Dupixent vs Skyrizi
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| CA Dupixent | CA Skyrizi | |
|---|---|---|
| Generic name | dupilumab | risankizumab |
| Drug class | IL-4/IL-13 Inhibitor (Biologic) | IL-23 Inhibitor (Biologic) |
| Treats | Eczema, asthma, nasal polyps | Plaque psoriasis, psoriatic arthritis, Crohn's disease |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Sanofi/Regeneron | AbbVie |
| Year approved | 2017 | 2019 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $65M | $48M |
| Common side effects | Injection site reactions, Conjunctivitis, Cold sores, Eosinophilia | Respiratory infections, Headache, Fatigue, Injection site reactions |
Frequently asked questions
Is Dupixent or Skyrizi better?
Neither is universally "better." Dupixent (dupilumab) and Skyrizi (risankizumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Dupixent and Skyrizi?
Dupixent is a IL-4/IL-13 Inhibitor (Biologic) made by Sanofi/Regeneron, while Skyrizi is a IL-23 Inhibitor (Biologic) made by AbbVie. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Dupixent has the larger estimated TV advertising budget of the two.